Disclosures under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011
INDSWFTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.5 pts less than Nifty Microcap 250 and 2.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
HCP Investments, a Mauritius-based investment entity, sold 6,503,423 equity shares (7.5%) of Ind-Swift Laboratories Limited in the open market between April 13-17, 2026. Before the sale, HCP held 7,500,000 shares (8.649% of share capital). After completing the disposal, their remaining holding is 996,577 shares (1.149%). HCP Investments is not a promoter or person acting in concert with any promoter of the company. The sale was executed in multiple tranches across the specified dates.
This represents a significant exit by a substantial shareholder, reducing their stake from 8.65% to just 1.15%. The open market sale of such a large block (7.5%) could exert downward pressure on the stock price in the near term, as it signals reduced institutional backing from this investor.